Nektar to Report 22.7% Wider Loss on 67.3% Revenue Slide
Nektar Therapeutics is forecast to report a 22.7% wider loss of $2.76 per share on a 67.3% drop in revenue to $9.54M for the quarter ended December 2025. Analysts have trimmed estimates, driving a -48.28% Earnings ESP despite a Zacks Rank 2 and signaling low odds of an EPS beat.
1. Q4 Earnings Expectations
Nektar is expected to post a loss of $2.76 per share for the quarter ended December 2025, representing a 22.7% wider loss compared to the prior year. Revenue is projected at $9.54 million, down 67.3%, with the report due on March 12 and poised to move the stock if results diverge from forecasts.
2. Estimate Revisions and Earnings ESP
Over the last 30 days, the consensus EPS estimate has risen 7.57%, yet the most recent analyst projections remain below the consensus, yielding a -48.28% Earnings ESP. This negative ESP, paired with a Zacks Rank of 2, indicates mixed signals for a potential earnings beat.
3. Historical EPS Surprise Pattern
In the prior quarter, Nektar delivered a loss of $1.85 per share versus an expected $2.85 loss, a positive surprise of 35.1%. The company has beaten consensus EPS estimates in two of the last four quarters, highlighting occasional upside against expectations.